Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy

Liver

Volumn 19, Issue 5, 1999, Pages 389-398

  Taylor Robinson, Simon D ^a,b   Buckley, Camilla ^a,b   Changani, K Kumar ^a   Hodgson, Humphrey J F ^b   Bell, Jimmy D ^a  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Basal ganglia; Glutamine; High energy phosphates; Magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE; ESTER; GLUTAMIC ACID; GLUTAMINE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; MALE; OCCIPITAL CORTEX; PARIETAL LOBE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL CORTEX;

ADULT; AGED; BRAIN; CHOLINE; CREATININE; ELECTROENCEPHALOGRAPHY; FEMALE; GLUTAMIC ACID; GLUTAMINE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOSPHATES; PHOSPHORUS ISOTOPES; PROTONS;

EID: 0032882570     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00067.x     Document Type: Article

References (49)

1. ROSS B D, KREIS R, ERNST T. Clinical tools for the 90s: magnetic resonance spectroscopy and metabolite imaging. Eur J Rad 1992; 14: 128-40.
2. COUTTS G A, COX I J, GADIAN D G, et al. Phosphorus-31 magnetic resonance spectroscopy of the normal human brain. Approaches using four-dimensional chemical shift imaging and phase mapping techniques. NMR Biomed 1989; 1: 190-7.
3. 31P MRS. Clin Sci (Colch) 1987; 72: 26P.
4. 1H NMR spectroscopy of the human brain in chronic hepatic encephalopathy. Proc 8th Ann Mtg Soc Magn Reson Med 1989; 1: 375.
5. CHAMULEAU R A F M, BOSMAN D K, BOVÉE W M M J, LUYTEN P R, BARKHOF F. Chronic hepatic encephalopathy studied by NMR spectroscopy and MRI in man. J Hepatol 1991; 13: S19.
6. 31PMRS in patients with chronic liver disease Proc 11th Ann Mtg Soc Magn Reson Med 1992; 3: 1919.
7. 31P MRS in liver cirrhosis. Hepatogastroenterology 1993; 40: 6/0.
8. TAYLOR-ROBINSON S D, SARGENTONI J, MALLALIEU R J, et al. Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology 1994; 20: 1173-8.
9. TAYLOR-ROBINSON S D, SARGENTONI J, OATRIDGE A, et al. MR imaging and spectroscopy of the basal ganglia in chronic liver disease: Correlation of T1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra Metab Brain Dis 1996; 11: 249-68.
10. RUIZ-CABELLO J, COHEN J S. Phospholipid metabolites as indicators of cancer cell function NMR Biomed 1992; 5: 226-33.
11. CHAMULEAU R A, BOSMAN D K, BOVÉE W M M J, LUYTEN P R, DEN HOLLANDER J A. What the clinician can learn from MR glutamine/glutamate assays. NMR Biomed 1991; 4: 103-8.
12. 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols NMR Biomed 1991; 4: 109-16.
13. KREIS R, ROSS B D, FARROW N A, ACKERMAN Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992; 182: 19-27.
14. ROSS B D, JACOBSEN S, VILLAMIL F, et al. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994; 193: 457-63.
15. TAYLOR-ROBINSON S D, SARGENTONI J, MARCUS C D, MORGAN M Y, BRYANT D J. Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy. Metab Brain Dis 1994; 9: 347-59.
16. KREIS R, ROSS B D, FARROW N A, ACKERMAN Z. Diagnosis of hepatic encephalopathy by proton magnetic resonance spectroscopy. Lancet 1990; 336: 635-6.
17. BRUHN H, MERBOLDT K D, MICHAELIS T, et al. Proton MRS of metabolic disturbances in the brain of patients with liver cirrhosis and subclinical hepatic encephalopathy. Proc 10th Ann Mtg Soc Magn Reson Med 1991; 1: 400.
18. HÄUSSINGER D, LAUBENBERGER J, VOM DAHL S, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994; 107: 1475-80.
19. LAUBENBERGER J, HÄUSSINGER D, BAYER S, GUFLER H, HENNIG J, LANGER M. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997; 112: 1610-6.
20. GEISSLER A, LOCK G, FREUND R, et al. Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. Hepatology 1997; 25: 48-54.
21. CONN H O, LEEVY C M, VLAHCEVIC Z R, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind trial. Gastroenterology 1977; 72: 573-83.
22. CONN H O. Trail making and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 541-50.
23. WECHSLER D. Wechsler Adult Intelligence Scale Manual. New York: Psychological Corporation, 1955.
24. KENDRICK D C, GIBSON A J, MOYES I G A. The revised Kendrick battery: clinical studies Br J Soc Clin Psychol 1979; 18: 329-39.
25. MORGAN M Y, ALONSO M, STANGER L C. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. J Hepatol 1989; 8: 208-17.
26. QUERO J C, HUIZENGA J R, CHAMULEAU RAFM, BLIJENBERG B G, GIPS C H, SCHALM S W. Determination of ammonia in capillary and arterial blood simultaneously using the BAC II. Hepatogastroenterology 1993; 40: 81.
27. PUGH R N H, MURRAY-LYON I M, DAWSON J L, PIETRONI M C, WILLIAMS R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1972; 60: 646-9.
28. SAEED N. A knowledge based approach to deconvolve the water component in in vivo proton MR spectroscopy. J Comput Assist Tomogr 1995; 19: 830-7.
29. BRYANT D J, WEEKS R A, MARCUS C D, SARGENTONI J, TAYLOR-ROBINSON S D, BROOKS D J. Glutamate in Huntington's disease. Lancet 1994; 344: 189-90.
30. TAYLOR-ROBINSON S D, WEEKS R A, BRYANT D J, et al. Proton MRS in Huntington's disease: evidence in favour of the glutamate excitotoxic theory? Mov Disord 1996; 11: 167-73.
31. TAYLOR-ROBINSON S D, WEEKS R A, SARGENTONI J, et al. Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet 1994; 343: 1170.
32. SAEED N, MENON D K. A knowledge-based approach to minimise baseline roll in chemical shift imaging. Magn Reson Med 1994; 29: 591-8.
33. BOTTOMLEY P A, HART H R, EDELSTEIN W A, et al. Anatomy and metabolism of the normal human brain studied by magnetic resonance at 1.5 Tesla. Radiology 1984; 150: 441-6.
34. ILES R A, GRIFFITHS J R, STEVENS A N. Perturbations in hepatic energy metabolism Biochem Soc Trans 1985; 13: 843-5.
35. RADDA G K, RAJAGOPALAN B, TAYLOR D J. Biochemistry in vivo: an appraisal of clinical magnetic resonance spectroscopy Magn Reson Quart 1989; 5: 122-51.
36. HÄUSSINGER D. The role of cellular hydration in the regulation of cell function. Biochem J 1996; 313: 697-710.
37. BUTTERWORTH R F, GIGUERE J F, MICHAUD J, LAVOIE J, LAYRARGUES G P. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-12.
38. STAHL J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic and therapeutic significance. Ann Intern Med 1963; 58: 1-24.
39. FISCHER J E. Portal-systemic encephalopathy. In: Millward-Sadler G H, Wright R, Arthur M J P, eds. Wright's liver and biliary disease. London: WB Saunders Company Ltd., 1993: 1262-95.
40. ROSS B D, DANIELSEN E R, BLUML S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? Dig Dis 1996; 14: 30-9.
41. 1H NMR spectroscopy: N-acetyl aspartate, creatine and choline. NMR Biomed 1991; 4: 47-52.
42. JAMES J H, ESCOURROU J, FISCHER J E. Blood-brain neutral amino acid transport activity is increased after portacaval anastomosis. Science 1978; 200: 1395-7.
43. HAWKINS R A, MANS A M, BIEBUYK J F. Changes in brain metabolism in hepatic encephalopathy. Neurochem Pathol 1987; 6: 35-66.
44. SCHENKER S, BRADY C E III. Pathogenesis of hepatic encephalopathy. In: Conn H O, Bircher J eds. Hepatic encephalopathy: syndromes and therapies. Bloomington: Medi-Ed Press, 1994: 43-61.
45. 31P magnetic resonance of the normal liver: towards in vivo biochemical pathology. Clin Sci (Colch) 1992; 83: 183-90.
46. TAYLOR-ROBINSON S D, SARGENTONI J, BELL J D, et al. In vivo and in vitro hepatic phosphorus-31 magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver 1997; 17: 198-209.
47. TAYLOR-ROBINSON S D, SARGENTONI J, BELL J D, et al. In vivo and in vitro hepatic phosphorus-31 magnetic resonance spectroscopy and electron microscopy in chronic ductopenic rejection of human liver allografts. Gut 1998; 42: 735-43.
48. JESSY J, DE JOSEPH M R, HAWKINS R A. Hyperammonaemia depresses glucose consumption throughout the brain. Biochem J 1990; 277: 693-6.
49. HILGIER W, BENVENISTE H, DIEMER N H, ALBRECHT J. Decreased glucose utilisation in discrete brain regions of rat in thioacetamide-induced hepatic encephalopathy as measured with (3H)-deoxyglucose. Acta Neurol Scand 1991; 83: 353-5.